Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4220-z
Abstract: PurposeThe aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated 212Pb-based alpha therapy… read more here.
Keywords: ca012; alpha therapy; 203pb 212pb; dosimetry ... See more keywords